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ABSTRACT 
 
BACKGROUND AND OBJECTIVES 
Intravenous regional anaesthesia (IVRA) using Lignocaine is a safe, reliable, 
and cost-effective technique for providing anaesthesia as well as bloodless field 
during upper limb surgery. It has been postulated that the site of action in IVRA is 
probably by blockade of small nerves or possibly nerve endings and not the major 
nerve trunks. A disadvantage of this technique is the rapid return of sensation after 
tourniquet release resulting in subsequent pain. 
The ideal IVRA solution should have rapid onset, require less dose of local 
anaesthetic (LA), reduce tourniquet pain, and prolong post-deflation analgesia.   
In this study we evaluated the effects of Paracetamol on onset of sensory and 
motor block time, sensory and motor recovery time and the requirement of 
postoperative analgesia. 
 
METHODS 
Sixty patients undergoing upper limb extremity surgeries were randomised into 
two groups .IVRA was achieved by injecting 10 ml of 2% Lignocaine with 30 ml of 
Paracetamol to total of 40 ml in Group 1(n=30) and 10 ml of 2% Lignocaine with 30 
ml of Normal saline to total of 40 ml in Group 2(n=30). Onset of sensory and motor 
block time noted, intraoperative pain assessed using VAS scores, intraoperative 
analgesic use and sensory and motor recovery time were noted during the surgery. 
Postoperative analgesic requirement was noted after the tourniquet deflation. Vital 
parameters were monitored throughout the operative period. 
 
RESULTS 
 Onset of sensory and motor block was shorter and sensory recovery time was 
longer in Group 1 (p < 0.001). Intraoperative VAS scores were significantly lower in 
Group 1 (p< 0.05). Intraoperative Fentanyl consumption was 8.33 ± 21.82 mcg in 
Group 1 and 38 ± 37.82 mcg in Group 2, the number of patients requiring Fentanyl 
were 4 and 17 respectively ( p< 0.001). The postoperative analgesia requirement was 
lower in Group 1 with 9 patients and was 25 patients in Group 2 (p< 0.001). 
 
CONCLUSION 
 The administration of Paracetamol as an adjunct to Lignocaine in IVRA was 
found to be efficacious and it provided significant shortening in the onset of sensory 
block, a decrease in the intraoperative analgesic requirement and an improvement in 
the post operative analgesia with a reduced need for analgesics in the post operative 
period. 
  
KEYWORDS: IVRA, Paracetamol, Lignocaine, VAS scores, Fentanyl 
 
1. INTRODUCTION 
 
Intra Venous Regional Anaesthesia (IVRA) is a regional anaesthetic technique 
commonly used in forearm surgeries. It was first introduced by a German surgeon 
August Gustav Bier in 1908 by injecting Procaine intravenously between two 
tourniquets1. He found that there was a rapid onset of anaesthesia between the 
tourniquets and a slower onset beyond the distal tourniquet. This technique gained 
more importance in the late 1960s after its reintroduction by Holmes2.  
There have been many modifications to this technique over time, presently the 
use of double tourniquet with injection of drugs distal to the cuffs. Its use has been 
proved to have an advantage of faster recovery, shorter hospital stay, cost 
effectiveness and reduced nursing care requirements making it an ideal choice for Day 
care surgeries3. 
When IVRA is appropriately performed there is a 96 - 100% success rate4-6. 
This technique has the advantage of rapid return of sensory and motor power at the 
end of surgical procedure allowing normal functioning of the operated limb and the 
surgeons are able to assess neurological status after surgery. This rapid recovery 
facilitates early discharge of patients. 
 IVRA is advantageous being reliable, easy to administer and cost-effective for 
short operative procedures of the extremities performed on an ambulatory basis3. 
There are some disadvantages like delayed onset of action, poor muscle relaxation and 
rapid onset of pain at operative site after tourniquet is deflated7.  
 Various additives like Opioids, Muscle relaxants, NSAIDs such as Ketorolac8, 
Tenoxicam9 and Aspirin10 have been used to overcome these disadvantages to 
improve analgesia. 
  There is a risk of local anaesthetic toxicity due to sudden release of large 
amounts of local anaesthetic as a result of leakage due to high venous pressure or 
accidental tourniquet failure past the inflated tourniquet. Due to the above mentioned 
effects it is desirable to limit the amount of local anaesthetic to a minimum11. 
In previous studies, IVRA with Paracetamol was shown to improve overall 
quality of the block, early onset of motor block, reduced tourniquet pain, delayed 
recovery of motor and sensory block, low intraoperative pain scores and decreased 
analgesic requirements both during intraoperative and post operative period. 
The ideal IVRA solution should have rapid onset of action, require less amount 
of local anaesthetic, reduce tourniquet pain and prolong post-deflation analgesia. This 
may be achieved by addition of adjuncts to local anaesthetic.  Paracetamol added as an 
adjunct to Lignocaine has been shown to provide decreased tourniquet pain, increased 
anaesthesia quality and decreased postoperative analgesic consumption.  
 
 
 
2. AIM AND OBJECTIVES OF THE STUDY 
 
 
PRIMARY OBJECTIVES:  
To determine the efficacy of Paracetamol when added as an adjuvant to 
Lignocaine for IVRA. 
 
SECONDARY OBJECTIVES: 
 To compare the 
1) Onset of sensory and motor block in both groups 
2) Sensory and Motor recovery time in both groups 
3) Requirement of post operative analgesia 
 
 
 
 
 
 
 
 
 
 
3. REVIEW OF LITERATURE 
 
Holmes et al1 opined that Procaine produced patchy anaesthesia; so he 
replaced it with Lignocaine. In 1963 he conducted a study on 30 patients with 0.5% 
Lignocaine. He used 25 to 60 ml of 0.5% Lignocaine for 29 patients and 0.25% for 1 
patient. The dose of 0.25% was found to be ineffective. Analgesia was complete in 21 
cases with 0.5% Lignocaine.  In 7 patients, surgery was performed satisfactorily but 
patients had discomfort and failure of technique in 2 cases. Motor power and sensation 
returned back within 5 to 10 minutes of the tourniquet release. 
 
Chan VW et al3 postulated that IVRA can offer a more favourable patient 
recovery, shorter post operative care and early discharge than an Isoflurane based 
general anaesthesia or brachial plexus block technique for hand surgery. 
 
Perlas A et al7 observed the use of forearm tourniquet as a rescue cuff when 
there was tourniquet pain. Inflation of the proximal cuff was common to both the 
groups and IVRA with 0.5% Lignocaine at 0.6 ml/kg was given. When there was 
tourniquet pain, the distal cuff in the double cuff tourniquet was inflated in the first 
group and a single forearm cuff as rescue cuff in the second group. From the study, it 
was concluded that there was better tolerance with forearm rescue cuff with lower 
pain scores, longer tourniquet tolerance and less side effects. 
Reuben SS et al8 conducted a study using the parenterally available NSAIDs -
Ketorolac as a component of IVRA which suppressed intraoperative tourniquet pain 
and enhanced post operative analgesia. It was concluded that Ketorolac improves 
IVRA with 0.5% Lignocaine both in terms of controlling intraoperative tourniquet 
pain and by decreased post operative pain. 
 
Vishala G et al11 compared the analgesic effects of IVRA between Lignocaine 
and Paracetamol with Lignocaine. In their study, one group received 40 ml of 0.5% 
Lignocaine and another group received 10 ml of 2% Lignocaine with 30 ml 
Paracetamol. From their study, it was inferred that onset of motor block, 
intraoperative rescue analgesia, recovery of sensory block and postoperative analgesia 
were statistically significant in the group which received Paracetamol. 
 
Turan A et al12 evaluated the effects of Neostigmine when added to Prilocaine 
for IVRA. Onset and recovery of sensory and motor block, and anaesthesia quality 
was determined by an anaesthesiologist. The operating field dryness and anaesthesia 
quality was noted during the study by the surgeon. It was concluded that Neostigmine 
as an adjunct to Prilocaine improved the quality of anaesthesia and is beneficial in 
IVRA.  
 
Choyce A et al13 reviewed the use of adjuncts in IVRA for surgical procedures 
in terms of their intraoperative effects, efficacy of block, tourniquet pain and post 
operative analgesia. Using NSAIDs or Clonidine as adjuncts to IVRA improved motor 
block and post operative analgesia. 
 
Sen H et al14 evaluated the effect of Paracetamol on onset of sensory and 
motor block, tourniquet pain and post operative analgesia when added to Lignocaine 
in IVRA. The addition of Paracetamol during IVRA with Lignocaine was shown to 
decrease tourniquet pain, increase anaesthesia quality and decrease post operative 
analgesic consumption. 
 
Bertolini and colleagues15 observed that Paracetamol had a peculiar analgesic 
and antipyretic property which neither caused anti-inflammatory response nor any 
gastric side effects but characterized by a sense of relaxation and tranquility. It led to 
the discovery that Paracetamol acts as a prodrug (Cannabinomimetic) triggered by the 
CB1 receptors of the Cannabinoid system proving the peculiar action of paracetamol. 
 
Blond L and Madesan J L16 in their study had evaluated the exsanguination 
of the upper limb by elevation alone, or by use of Esmarch or gauze bandages, 
squeeze methods and using the Urias bag. By the above procedures, the reduction in 
blood volume with elevation alone during 5,15,30,60 seconds & 4 minutes was 44%, 
45%, 46%, 46% and 42% respectively; whereas the reduction was 63 % with Esmarch 
bandage, 53% by squeeze method  and 57% by Urias bag method. From this study, it 
was inferred that Esmarch bandage was the most effective exsanguination method but 
its sterilization and application was time consuming. Urias bag takes time to apply in 
exsanguination making its use ineffective. Squeeze method was found to be practical 
as it was fast and inexpensive but not effective as the external applicators.  
 
Boas R A et al17 conducted a study to evaluate the analgesic effect of 
intravenous Lignocaine. They had selected five patients and produced ischemic pain 
of equal intensity to their clinical pain by applying and inflating tourniquet on upper 
arm. At that point they gave Lignocaine 3mg/kg intravenously and observed initial 
decline in both ischemic and clinical pain when arterial Lignocaine level was above 3 
microgram/ml. As the Lignocaine concentration decreased below 3 microgram/ml the 
severity of ischemic pain increased. 
 
Jagger K.S et al18 mentioned that for IVRA, agents like Chlorprocaine, 
Prilocaine, Mepivacaine and Lignocaine were used, with each drug having its own 
disadvantage. Chlorprocaine produced an incidence of 37.5% central nervous system 
effects and thrombophlebitis. Prilocaine caused methaemoglobinemia and 
Mepivacaine had an inconvenient dosage scheme. Lignocaine remained as the popular 
agent for the technique. However the dosage found to produce desirable effect had 
several side effects like dizziness, tinnitus and cardiac dysarrhythmias. 
 Reuben S.S et al19 in another study compared wound infiltration of Ketorolac 
versus IVRA with Ketorolac for postoperative analgesia following ambulatory hand 
surgery. This study consisted of 60 patients who were divided into three groups of 20 
each. All patients received IVRA with 40ml 0.5% Lignocaine and 5ml 1% Lignocaine 
infiltrated into the surgical site. Group 1, the control group received no additional 
medications. Group 2 had 60mg Ketorolac added to Lignocaine for IVRA and Group 
3 had 60mg Ketorolac added to Lignocaine for wound infiltration. Post operative pain 
was assessed by a Visual Analogue Scale (VAS) 1 hour and 2 hours after IVRA. They 
were assessed for additional requirement of narcotics and Acetaminophen with 
Codeine tablets. The conclusion was Ketorolac provides similar post operative 
analgesia after ambulatory hand surgery when administered with Lignocaine either by 
IVRA or by wound infiltration. 
 
Arregui-martinez-de-hejarza LM et al20 studied the analgesic effectiveness 
of Ketorolac in IVRA induced by Lignocaine. They conducted a double blinded 
placebo controlled clinical trial on 26 patients undergoing elective surgery on the 
upper extremities who were divided into two groups. They received 3mg/kg of 0.5% 
Lignocaine either with 1 ml of 0.9% saline solution for control group or 1 ml with 30 
mg of Ketorolac for the treatment group. They were assessed for postoperative pain on 
a VAS over the first 24 hours. The data were compared using student t test for 
parametric variables and Mann-Whitney test and Fisher’s exact test for non-parametric 
variables. They found 10 out of 13 patients in control group required analgesia within 
first two hours whereas none in the treatment group required analgesia.  
 
Geoffrey T. Tucker et al21 studied the kinetics of deposition of Lignocaine 
after IVRA of the arm and direct intravenous infusions. They found that peak plasma 
levels of Lignocaine after the release of cuff were 20 to 80% lower than those found 
when the same dose was given directly into a vein over 3 minutes. Peak levels after 
release of cuff were inversely proportional to duration of tourniquet application. They 
also tend to be lower when the same dose was given in 0.5% instead of 1% solution. 
Following the first few minutes after release of tourniquet cuff, there was distribution 
of Lignocaine within pulmonary system buffering the vital organs against high levels 
of the drug. 
 
Raj et al22 studied the site of action of local anaesthetic agents in intravenous 
regional anaesthesia. According to them local analgesic agent can block the nerves at 
the elbow by 
1. Central axis system 
2. Peripheral venous plexus in neural sheath 
3. Anastamosing channels between central axis system and peripheral venous 
plexus 
4. Direct perfusion 
Since the fibres to the distal part of the extremity are in the core of the nerve trunk, 
while those to the proximal part are in the outer layers, the fibres of the distal 
extremity are blocked first. Their anaesthesia develops from the finger tips upwards 
when the solution is deposited in this region. 
 
Merryfield A.J et al23 studied the blood levels of Lignocaine in IVRA. They 
used 4 mg/kg of 0.5% Lignocaine solution, subjective symptoms appeared at a blood 
level approximately 5 mcg/ml. They stated that even below the dose 2 mg/kg can 
produce subjective symptoms and this amount will not often produce adequate 
analgesia. They suggested that the dose 4 mg/kg found necessary for good analgesia 
was safe, provided the release into the circulation is delayed. 
 
Sorbie C et al24 reported the use of IVRA in 128 patients. In his study 15 
patients out of 128 had discomfort at operative site and were classified as having 
unsuccessful anaesthetics. They used 0.5% Lignocaine and the maximum dose was 
200 mg for the arm, no serious effects were found during surgery or tourniquet 
release. 
 
Steinberg RB et al25 studied the dose response relationship of Ketorolac as a 
component of IVRA with Lignocaine. They added 0, 5, 10, 15, 20, 30 and 60 mg of 
Ketorolac to 0.5% Lignocaine IVRA for either carpal tunnel release or tenolysis. 
There were no significant differences among the groups who received 20, 30 or 60 mg 
of Ketorolac. They concluded that 20 mg of Ketorolac was the optimal dose for 
inclusion with 0.5% Lignocaine for IVRA under the conditions of their study. 
 
Niemi T.T et al26 studied the haemostatic changes caused by IVRA when used 
with Lignocaine. This study was performed on 10 healthy volunteers to examine the 
role of Lignocaine in IVRA to detect haemostatic changes particularly the fibrinolytic 
pathway and platelet function. It was concluded that there was activation of 
fibrinolysis and no alteration of platelet function when there was high concentrations 
of Lignocaine in the limb where tourniquet was applied. 
 
 
 
 
 
 
 
 
 
HISTORY 
AUGUST KARL GUSTAV BIER (1861- 1949) 
August Bier was born in Bad Arolsen in Waldeck-Frankenberg in Germany on 
24th November 1861. He graduated from the University of Kiel in 1889 where he later 
became an assistant to Friedrich Von Esmarch, professor of surgery. He familiarised 
the work done in a medical college in Kiel by Heinrich Irenaeus Quincke who 
established lumbar puncture as safe investigation in routine neurological examination. 
 
FIGURE 1. AUGUST BIER 
On August 16th 1898, Bier performed the first surgery under spinal anaesthesia 
at Royal surgical hospital under the University of Kiel. Later in the same year Bier 
received spinal anaesthetic by his assistant August Hilderbrandt to prove the 
anaesthetic effects which was successful. 
 In addition to this discovery he invented the method of treating chronic 
inflammation by the method of passive hyperaemia with Esmarch’s bandage and 
pioneered intravenous Procaine analgesia in 1908. He was a great figure of German 
surgery as a teacher, a lecturer and a surgeon. He introduced the tin helmet into the 
German army in the First World War. He died at the age of 88 years on 12th March 
1949. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANATOMY: 
The relevant anatomy in IVRA is the location and distribution of peripheral 
veins in the extremity to be blocked. A vein as distal as possible is chosen. 
Cannulation at the surgical site is best avoided.  
The superficial veins of the upper limb form many patterns. The dorsal venous 
arch lies on the dorsum of the hand and receives many digital branches. It ends 
medially as Basilic vein and laterally as Cephalic vein.  
The Cephalic vein is the preaxial vein of the upper limb; it crosses the 
anatomical snuff box superficial to the radial nerve. It ascends on the radial border of 
the forearm in the lateral bicipital furrow of the arm and runs in between the deltoid 
and pectoralis major muscles at the shoulder. It pierces the Clavipectoral fascia and 
ends in the Axillary vein.  
The Basilic vein is the postaxial vein of the upperlimb, it ascends on the ulnar 
side of the forearm to the elbow and runs in the medial bicipital furrow to the middle 
of the arm where it pierces the deep fascia. It then accompanies the Brachial artery to 
the axilla and becomes the Axillary vein. 
The Median Cubital vein lies in front of the elbow which joins the cephalic to 
the Basilic vein. The bicipital aponeurosis separates the Median Cubital vein from the 
Brachial artery and Median vein. 
 FIGURE 2. VENOUS SYSTEM OF THE UPPER LIMB 
MECHANISM OF ACTION: 
Mechanisms of IVRA are multiple, depending primarily on ischemia and on 
the transport of local anaesthetic solution through venous network into veins near the 
nerve trunks. Nerve trunks in the extremities are composed of a connective tissue 
layer called epineurium containing blood vessels supplying the nerves. The 
endoneurium encloses individual nerve fibers containing capillary plexuses extending 
intraneurally as vasae nervorum. There is diffusion of local anaesthetic into small 
veins surrounding the nerves, the vasae nervorum and capillary plexus leading to a 
centrifugal neural blockade. There is diffusion into smaller nerves in skin blocking the 
conduction. It is said that tourniquet inflation causes ischaemia which contributes to 
analgesic action of the local anaesthetic by blocking conduction and motor endplate 
function27.                                                                                         
Initial effect - Blockage of small peripheral nerves and nerve endings 
↓ 
Diffusion – Blockage of large nerves at proximal sites and intraneural venous 
distribution of local anaesthetic 
↓ 
Ischemia - Blockage of nerve conduction and motor end-plate function 
↓ 
Compression – Nerves under the tourniquet cuff gets compressed 
INDICATIONS: 
1) Duration of procedure not exceeding  more than 1 hour 
2) Surgeries on forearm and hand which includes 
a) Manipulation of forearm fractures 
b) Excision of wrist ganglia 
c) Tendon grafting or tendon repair 
d) Suturing of major lacerations in forearm or hand 
e) Debridement of burn areas in forearm or hand 
  
CONTRAINDICATIONS: 
ABSOLUTE: 
1) Patient refusal  
2) Allergy to local anaesthetics 
3) Uncontrolled hypertension hindering tourniquet inflation. 
 
RELATIVE: 
1) Patient uncooperative during procedure 
2) Raynaud’s disease 
3) Buerger’s disease 
4) Sickle cell disease 
5) Crushed extremities causing transient ischaemia due to hypoxia 
6) Continuous cardiac or blood pressure monitoring required 
7) Inability to assess  peripheral veins 
8) Skin infection or cellulitis 
9) Disruptions in the integrity of venous system 
10) Skeletal muscle disorders 
11) Paget’s disease – local anaesthetics may spread to systemic circulation via   
venous channels in bone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGY: 
LIGNOCAINE HYDROCHLORIDE  
 Local anaesthetic  
 Class – 1b   antiarrhythmic drug  
History:  
In 1860 Albert Nieman purified the alkaloid extracted from Coca leaves and 
named it Cocaine. In 1884 Karl Koller used Cocaine as a topical ophthalmic 
anaesthetic. Nils Lofgren in 1943 a Swedish chemist synthesised first amino amide 
local anaesthetic.  His colleague Bengt Lundqvist injected the drug himself to prove 
its anaesthetic properties. It was first marketed in 1949. 
Trade names  : Xylocaine  
                           Xylocard (preservative free) used intravenously 
Routes of administration :  Intravenous, subcutaneous, topical, oral solutions      
                                                        and epidural  
Bioavailability  : Oral - 35% 
                                          Topical – 3% 
Half life   :           1.5 – 2 hours 
Metabolism   :          Hepatic 90% by CYP1A2  
Excretion  :         Renal system 
IUPAC name :         2-(diethylamino)-N-(2, 6-dimethylphenyl)acetamide 
Formula  : C14H22N2O 
Molecular mass :          234.34 g/mol 
Melting point :  680C 
Therapeutic range :  1.5 – 5 mcg/ml 
Structure  : 
 
 
 
FIGURE 3. STRUCTURE OF LIGNOCAINE HYDROCHLORIDE 
 
 Mechanism of action of Lignocaine: 
The primary action of Lignocaine is on the cell membrane of the axon, on 
which it produces electrical stabilisation. The large transient increase in permeability 
to sodium ions necessary for propagation of the impulse is prevented, thus the resting 
potential is maintained and depolarisation in response to stimulation is inhibited. 
Initially the threshold for electrical excitation is raised, the rate of rise of action 
potential is reduced and conduction slowed, eventually propagation of the impulse 
fails28. 
It has a dual effect on the cell membrane to produce these effects  
1) Action on the axoplasmic opening of the sodium channels 
2)  Non-specific physiochemical effect within cell membrane 
 
1) Action on the axoplasmic opening of the sodium channels : 
It is hypothesised that it acts on specific receptors. This is shared by quartenary 
derivatives of Lignocaine being fully ionised, that cannot penetrate the cell membrane 
which produce nerve blockade only if applied to its inner surface. Similarly amide 
local anaesthetics act principally in the cationic form and on the axoplasmic surface of 
the membrane. This suggests that local anaesthetics impair sodium permeability by an 
action blocking the internal openings of sodium channels. This action accounts for 
90% of the nerve conduction blocking effect of Lignocaine. 
 2) Non-specific physiochemical effect within cell membrane: 
This is a non-specific action in contrast to a more specific drug receptor interaction 
and is analogous to the electrical stabilisation produced by a number of non-polar, 
purely lipid substance such as non-ionised Barbiturates, general anaesthetics and 
Benzocaine. 
The production of nerve conduction blockade is associated with about 3-5 % 
expansion of membrane volume. The actual volume of anaesthetic occupying the 
membrane however is only 0.3 % or less. Since the volume occupied by the 
anaesthetics accounts for 10 % of this membrane expansion, a number of mechanisms 
have been suggested to account for further 90 %.  
The most likely explanation is that there is unfolding of membrane protein, 
together with a disordering of the liquid component of the cell membrane, with 
consequent obstruction of the sodium channels. Displacement of membrane bound 
calcium ions may also be involved. Calcium is known to condense lipid layers and 
local anaesthetics to displace it. The mechanism may account for the lesser part of the 
effect of Lignocaine. 
It stabilises the neuronal membrane by inhibiting the ionic fluxes required for 
initiation and conduction of impulses effecting local anaesthetic action. Efficacy of 
Lignocaine is characterised by its rapid onset of action and intermediate duration of 
action so used for infiltration, blocks and surface anaesthesia. 
  
 
FIGURE 4. INTERACTION OF LOCAL ANAESTHETICS WITH  
SODIUM   CHANNELS 
 The blocking site within the channel can be reached either through the open 
channel gate on the inner surface of the membrane by the charged species BH+ 
(hydrophilic pathway) or directly from the membrane by the uncharged species B 
(hydrophobic pathway)29. 
Analysis of local anaesthetic action has shown many drugs exhibit the property of 
‘use dependent’ block of sodium channels and to some extent the gating of the 
channels28. Use dependence means more the channels are open the greater the block. 
This occurs because the blocking molecule enters the channel more readily when 
opened than when closed29. 
Channels can exist in three functional states: resting, open and inactivated. Many 
local anaesthetics bind strongly to the channels in inactivated state, therefore at any 
given membrane potential the equilibrium between the resting and inactivated 
channels will be in favour of the inactivated channels. This contributes to the overall 
blocking effect, by reducing the number of channels available for opening and by 
prolonging refractory period following an action potential29. 
When a painful stimulus is applied to a sensory nerve it causes the channels to 
cycle through open and inactivated states, both of which are more likely to bind the 
local anaesthetic than the resting state. These mechanisms contribute to use- 
dependence which explains why transmission may be blocked more effectively than 
other sensory modalities29. 
 
 Impulse blockade by local anaesthetics29: 
1. By deposition of local anaesthetic near the nerves, most of the free drug 
molecules are removed by tissue binding, circulation and hydrolysis of aminoester 
anaesthetics and the remaining free drug is penetrated into the nerve sheath. 
2. Penetration into nerve’s axon and axoplasm depends on the drug’s pKa and 
lipophilicity. 
3. Binding to voltage-gated Sodium channels prevents the opening of these 
channels as local anaesthetic binds to the channel’s pore occluding the path of the 
Sodium channels
.
 
4. Impulse blockade is incomplete during onset and recovery from local 
anaesthetics. Repeated stimulation produces dose dependent binding to Sodium 
channels. 
5. Binding site on Sodium channel which produces drug’s resting and dose 
dependent action is accessed through hydrophobic approach from within the axon 
membrane. 
6. The rate of onset and recovery from blockade are regulated by the slow 
diffusion of local anaesthetics in and out of the nerves, not by their fast binding and 
dissociation from ion channels. 
 
Insensitivity:  
Relative insensitivity is genetic and is commonly seen in hypokalemic sensory 
overstimulation and attention deficit hyperactivity disorder. Ehlers-Danlos syndrome 
patients are also insensitive to Lignocaine. 
 
Contraindications: 
Absolute 
1. Heart block – second or third degree not on pacemaker 
2. Sinoatrial block not on pacemaker 
3. Adverse drug reactions to Lignocaine or other amide local anaesthetics. 
4. Hypersensitivity to corn or corn related products as dextrose used is derived 
from corn 
5. Class 1 antiarrthymic drugs used concurrently  
6. Prior use of Amiodarone hydrochloride   
7. Adams- stokes syndrome30 
8. Wolff – Parkinson – White syndrome30 
Relative 
1. Hypotension not related to arrhythmia 
2. Bradycardia 
3. Accelerated idioventricular rhythm 
4. Elderly patients 
5. Pseudocholinesterase deficiency 
6. Porphyria 
7. Impaired liver function 
 
Adverse Effects 
1) Central Nervous System: 
Nervousness, agitation, anxiety, apprehension, circumoral paraesthesia- 
tingling sensation around mouth, tremors, dizziness, papillary changes, 
hallucinations, euphoria, psychosis and seizures31. 
2) Cardiovascular System: 
Bradycardia, hypotension, arrhythmias, flushing, venous insufficiency, 
increased defibrillator threshold and cardiac arrest31, may be due to 
hypoxaemia secondary to respiratory depression32. 
3) Respiratory System: 
Bronchospasm , dyspnoea , respiratory depression and respiratory arrest31. 
4) Gastrointestinal System: 
Nausea, vomiting and metallic taste31   
5) Others: 
Tinnitus, allergy,  conjunctival hyperaemia, corneal epithelial opacification or 
ulceration, urticaria, itching, methemoglobinemia and hypersensitivity 
reactions31. Inflammation of veins can occur at the site of drug injection in 
IVRA techniques. 
 
Pharmacokinetics: 
Onset    :         45 to 90 seconds 
Duration   : 10 to 20 minutes 
Metabolism   : Dealkylation in liver by CYP3A4 
     Metabolites : 
     1.Active   –  Monoethylglycinexylidide  
     2.Inactive –  Glycine Xylidide 
Volume of Distribution :  1.1 to 2.1 L/Kg 
Elimination Half-Life :  90 to 120 Minutes 
Excretion   :           Urine - 90% Metabolites 
                                         10% Unchanged drug 
Drug interactions33: 
Factors altering protein binding will alter the availability of the drug in a free 
state. Renal and hepatic diseases are associated with high circulating levels of 
Lignocaine. 
Drugs like Isoproterenol and Adrenaline increase the hepatic blood flow. 
Concomitant administration of Phenytoin and Propranolol are associated with 
increase in free drug level in plasma. 
Phenobarbitone produces enzyme induction enhancing elimination of the drug 
from the body. 
Inhalational agents like Halothane, Fluroxene, Methoxyflurane enhance the 
lethal effects of the local anaesthetics with their cardiovascular system depressant 
action. 
Administration during Ether anaesthesia causes respiratory depression in 
spontaneously breathing patients.  
There is prolongation of Suxamethonium and non-depolarising muscle relaxant 
action.  
 
 
 
PARACETAMOL (ACETAMINOPHEN) 
History: 
Paracetamol was first synthesised in the year 1878 by Morse and later it was 
introduced for usage in 1883. In 1887 Von Mering used it clinically but discontinued 
after introduction of Phenacetin. In 1948 Brodie and Axelrod demonstrated the 
analgesic property of Paracetamol leading to its rediscovery and marketed since 
1950’s. 
  Intravenous route of administration started in the last decade and it was found 
to overcome the issue of bioavailability which limits speed of onset. Onset of 
analgesia occurs within 5 minutes with peak effect in 40-50 minutes and lasting for 4 
to 5 hours. 
Trade name   :  Perfalgan (Intravenous route) 
Routes of administration :  Oral, rectal and intravenous 
Bioavailability  :        63 to 89 % orally 
                                                        24 to 98% rectally 
Half-life   :     1-4 hours 
Metabolism   :   Hepatic system 
Excretion   : Renal system 
IUPAC name  : N (4-hydroxyphenyl) ethanamide 
N (4-hydroxyphenyl) acetamide 
Formula    :     C8H9NO2 
Molecular mass   :   151.163 g/mol 
Melting point   :    1690 C 
Density    :  1.263 g/ cm3 
Solubility in water   :      12.78 mg/ml 
Structure    : 
 
 
 
                           FIGURE 5. STRUCTURE OF PARACETAMOL 
 
Mechanism of action of Paracetamol: 
Paracetamol acts by the inhibition of Cyclooxygenase (COX) mediated 
production of Prostaglandin unlike the non steroidal anti inflammatory agents, so it 
was found that tissue inflammation was not reduced34, 35. 
 In intact cells levels of arachidonic acid were found to be low so the potent 
inhibitory action of Paracetamol on Prostaglandin synthesis blocks the physiological 
regeneration of Peroxidase (POX) 34, 35. 
 In broken cells concentration of Hydroperoxidase was found to be high; hence 
Prostaglandin synthesis inhibited weakly. This explains the differential activity of 
Paracetamol in the brain where peroxide concentrations are low and in peripheral sites 
of inflammation the levels were high. Hence at the site of injured or inflamed tissue it 
provides highly effective analgesia and antipyretic effects; but there is lack of 
antiinflammatory and anti platelet activity34, 35. 
Another pathway of action is by the activation of descending serotonergic 
pathway. Paracetamol also has an endocannabinoid enhancement activity which 
explains the experience of relaxation, tranquility and euphoria reported in many users 
apart from the analgesic effects15. 
 
 
 
               
FIGURE 6. CONVERSION OF PARACETAMOL TO AM404,  
AN ENDOCANNABINOID  REUPTAKE INHIBITOR 
 
 
 
Paracetamol is conjugated with Arachidonic acid in the presence of Fatty acid 
amide hydrolase(FAAH) to form the active metabolite N-arachidonoylphenolamine 
(AM404). This inhibits the reuptake of the endocannabinoid, anandamide from 
synaptic clefts, increasing the cannabinoid receptor activation on post synaptic 
membrane15. 
Onset of action36: 
Oral and rectal – 40 minutes; peak effect – 1 hour 
Intravenous      – 5 minutes;   peak effect – 40 to 60 minutes.  
 
Adverse Effects: 
1. Overdosage can cause liver damage 
2. Upper gastrointestinal bleeding 
3. Stevens – Johnson syndrome 
4. Toxic epidermal necrolysis  
5. Asthma 
6. Renal failure 
 
Overdosage: 
Nausea, vomiting, sweating and pain when acute liver failure starts. 
Toxicity is believed to be due to the accumulation of the Quinone metabolite. 
Untreated overdosage can lead to liver failure and death. 
Treatment is to remove Paracetamol from the body by replacing the 
Glutathione stores. It is either by using Activated charcoal (to decrease absorption of 
Paracetamol when a person presents with overdose) or using an antidote (N-
acetylcysteine or acetylcysteine). It acts as a precursor for Glutathione helping the 
body regenerate enough to prevent further damage to liver. 
PHARMACOKINETICS:  
Absorption :  Oral administration is rapidly absorbed in the       
gastrointestinal tract by passive transport 
Volume Of Distribution :  Approximately 50 litres ( 1 to 2 L/Kg) 
Metabolism           :   Occurs in liver into toxic and non-toxic products 
            Three pathways 
1. Glucuronidation accounts 45 to 55 % 
2. Sulfation – sulphate conjugation accounts for 20 to 30 %  
3. N-Hydroxylation and Dehydration accounts 15% 
The cytochrome P450 enzyme metabolises Paracetamol forming a metabolite 
N-acetyl-p-benzoquinone imine (NAPQI) also called as N-acetylimidoquinone which 
is irreversibly conjugated with sulfhydryl groups of Gluthathione. NAPQI production 
is primarily from isoenzymes of cytochrome P450 which are CYP2E1 and CYP3A4. 
The three pathways produce final products which are inactive and non-toxic 
excreted by kidneys. NAPQI is toxic which is responsible for toxic effects of 
paracetamol. At normal dose it is detoxified by conjugation with Glutathione76, 77, 78, 79. 
Elimination: 
1 to 4% is excreted unchanged in urine. Metabolic products are mainly 
excreted through the kidneys.  Rate of urinary clearance is 13.5L/h. 
 
Drug interactions15: 
Paracetamol potentiates the anticoagulant effects of acenocoumarol and 
warfarin, increasing the risk of bleeding. There is said to be an inhibition of the 
hepatic synthesis of coagulation factors 2, 7, 9 and 10 but not yet proved.  
Carbamazepine increases risk of hepatotoxicity by inducing the formation of 
toxic metabolites. There is lower bioavailability of Paracetamol when given with 
Phenytoin and Fosphenytoin.  
Coadministration with Zidovudine results in neutropenia and hepatotoxicity.  
Major concern is the interaction with alcohol. Alchohol- paracetamol syndrome 
is the development of acute toxic hepatic symptoms in long term alcoholics who 
consume Paracetamol at non-toxic doses. There is a worse prognosis than non- 
alcoholics overdosed with Paracetamol. With this syndrome the mortality is 20% and 
exceeds 75% if accompanied with acute liver failure. 
 
 
 
 
 
 
 
EQUIPMENT – TOURNIQUET DEVICES: 
1) PNEUMATIC TOURNIQUET 
History:  
Jean Louis Petit coined the term from French word “tourner” (to turn) in 1718. 
 
          FIGURE 7. JEAN LOUIS PETIT 
Mechanism: 
 It consists of inflatable cuff connected to compressed gas supply. This is 
connected to an instrument which monitors and controls cuff pressure. Pressure is 
exerted on the limb by compressed gas which is introduced into the cuff by a 
microprocessor source through connection tubings37.   
When sufficient pressure is exerted the vessels beneath tourniquet are 
occluded, preventing blood flow past the cuff. While cuff is inflated, tourniquet 
system automatically monitors the pressure chosen by the user. High pressures 
generated can be measured allowing controlled arterial compression. Audiovisual 
alarm alerts the user when there is cuff leak. 
Indications37:  
1) Surgeries on extremities – To reduce blood loss and provide good operative 
field 
2) Bier’s block – IVRA  
3) Management of complex regional pain syndrome – Intravenous regional 
sympathectomy  
4) Management of localised malignancy – Isolation of limb perfusion 
 
Pathophysiology:  
Effects on Cardiovascular system 
Cardiac arrest and circulatory overload commonly occur. It is believed that 
there is shift of blood volume into central circulation causing an increase in systemic 
vascular resistance and this leads to a transient rise in systolic blood pressure and 
central venous pressure38. 
Tourniquet pain is detected 30 – 60 minutes post inflation by gradual rise in 
arterial blood pressure and heart rate. Tourniquet deflation causes redistribution of 
circulating volume back into the limb and causes post ischemic reactive hyperaemia. 
Accumulated circulating metabolites are released back into systemic circulation and 
leads to a transient fall in arterial blood pressure and central venous pressure39, 40. 
Effects on Respiratory system 
Tourniquet inflation has minimal effects where as deflation leads to increase in 
end tidal concentration of carbon dioxide which peaks in 1 minute. There are two 
mechanisms to explain these effects, the first being increase in mixed venous PCO2 
caused by release of hypercapnic blood from ischemic area distal to tourniquet into 
systemic circulation. Secondly increase in cardiac output after deflation in response to 
decreased arterial pressure. This effect is more pronounced in lower limb tourniquet 
than upper limb tourniquet41, 42. 
  
Effects on Central nervous system 
Rapid increase in end tidal carbon dioxide after deflation causes increase in 
cerebral blood flow which peaks at 2 – 4 minutes and returns to baseline within 8 – 10 
minutes43, 44. This effect may cause secondary brain injury in patients with raised 
intracranial pressure. Normocapnia by hyperventilation after tourniquet deflation can 
prevent increase in cerebral blood flow and intracranial pressure45, 46, 47. 
 
Effects on Haematological system 
Inflation is associated with hypercoagulability towards the later stage of 
inflation and after deflation there is an increased thrombolytic effect. Pain due to 
tourniquet inflation and surgery causes release of catecholamines which promote 
platelet aggregation creating a hypercoaguble state48. Tissue ischemia after tourniquet 
inflation causes release of tissue plasminogen activator producing systemic 
thrombolysis on tourniquet deflation. After deflation there is a brief period of 
increased fibrinolysis peaking at 15 minutes and returning to preoperative levels 
within 30 minutes of deflation49. 
 
Temperature effects 
Core body temperature is increased during inflation due to reduced heat 
transfer and decreased heat loss from affected limb. Deflation causes fall in core 
temperature because of redistribution of body heat, in addition there is small amount 
of hypothermic blood from ischemic limb returned to systemic circulation50, 51. 
 
Metabolic changes 
After 1 to 2 hours of ischemia is increase in plasma potassium and lactate 
concentration after tourniquet release. Lactate and carbon dioxide from ischemic limb 
entering systemic circulation causes a reduction in arterial pH. Reperfusion of 
ischemic limb and other hemodynamic changes causes increase in oxygen 
consumption and carbon dioxide production post tourniquet release. All these effects 
are reversed within 30 minutes of release52. 
 
 
Tourniquet pain mechanism 
When tourniquet is inflated there is a vague dull pain in the limb associated 
with an increase in blood pressure, prolonged inflation causes increase in heart rate 
and further increase in blood pressure requiring interventions this is reffered to as 
tourniquet pain. Tourniquet pain is thought to be mediated by unmyelinated, slow C-
fibres that are normally inhibited by large, fast, myelinated A-delta fibres. Mechanical 
compression causes loss of conduction in nerve fibres blocking the large A-delta 
fibres before small C fibres53, 54,55,56,57. 
 
 
FIGURE 8. TOURNIQUET APPARATUS 
 
 
 Tourniquet pressures 
Two common practises regarding inflation pressures are using fixed pressure 
250 mmHg for upper limb and 300 mmHg for lower limb or by increasing cuff 
pressures 100 mmHg above systolic blood pressure for upper limbs and 100-150 
mmHg for lower limbs58. 
 
Contraindications 
1. Severe crush injuries to extremities 
2. Peripheral neuropathy in diabetic patients 
3. Sickle cell disease59 
4. History of deep vein thrombosis and pulmonary embolism  
5. Peripheral vascular disease 
 
Complications:  
1) Muscle injury: 
 Swelling and oedema can occur along with reperfusion hyperaemia. Muscle 
ischaemia, oedema and microvascular congestion leads to post tourniquet syndrome 
producing swollen, stiff and weak limbs. Rhabdomyolysis rarely occurs60. 
 
2) Nerve injury: 
 Complications range from paraesthesia to paralysis. High tourniquet pressures 
are implicated in cases of nerve damage. Using esmarch bandage increases likelihood 
of nerve injuries61. 
 
3) Skin injury: 
 Pressure necrosis and friction burns can occur due to badly applied 
tourniquets. Chemical burns are also quite common due seepage of alcohol based 
solutions during skin preparation beneath the tourniquet, held against the skin under 
pressure62, 63. 
4) Vascular injury:  
 Arterial injury is uncommon. Rush et al65 suggested  mechanical pressure can 
traumatise atheromatous vessel causing  plaques to rupture and the lack of blood flow 
as a result of tourniquet may cause thrombosis in atherosclerotic vesels64, 65. 
5) Intraoperative bleeding:  
Incomplete exsanguination can use intraoperative bleeding.  
 
 Tourniquet safety66, 67, 68:  
(i) Tourniquets should undergo regular maintenance checks like checking the 
aneroid gauge against suitable calibration device. 
(ii) Must be leak proof with no change in pressure over time 
(iii) Visually inspected prior to use with attention to rubber tubing, connections 
and cuff. 
(iv) Cuff circumference should exceed 7 – 15 cms more than the limb 
circumference and width appropriate to the size of the patient. 
(v) Avoid folding of tourniquet to protect skin from mechanical injuries 
(vi) Pressure gauge monitored continuously during use. 
 (vii) Arm adequately padded before applying tourniquet 
 (viii) Surgeons should be informed about the inflation time and alerted at 
frequent intervals when nearing deflation time  
(ix) Avoid seeping of bactericidal solutions beneath the tourniquet  
(x) Cautiously used in high risk patients like morbid obesity and previous 
peripheral vascular surgery.  
 
 
 
 
 
 
2) ESMARCH BANDAGE: 
History: 
Johann Friedrich August Von Esmarch (1823-1908) was a German surgeon 
who designed a two component device consisting of a rubber bandage attached with a 
strap to exsanguinate and occlude an arm or leg in battlefield injuries to combat the 
blood loss and limb injuries. 
 
FIGURE 9. JOHANN VON ESMARCH 
 
August Bier was the first to use this bandage in IVRA, but previously Johannes 
Von Esmarch and Henry A Martin used this bandage in the lower limb for treatment 
of static ulcers and in preventing recurrence of effusion in knee after aspiration. 
 
 
 FIGURE 10. ESMARCH BANDAGE 
Mechanism: 
In patients with traumatised arm or forearm, elevation or arterial compression 
by exsanguination techniques will sufficiently empty the veins. The degree of 
emptying the veins is related to the evenness and distribution of the local anaesthetic 
injected in the limb that does not affect the success of anaesthesia. 
If there is overfilling and distension of the veins, it causes swelling of adjoining 
tissue structures leading to oozing of blood obscuring the operating field during 
surgery. This problem can be overcome by using Esmarch bandage. 
Blond L et al16 observed 69% reduction in the blood volume of the arm when 
Esmarch bandage was used for exsanguinations, where as reduction of blood volume 
while elevating the arm alone causes only 44% reduction in the first 5 seconds, 46% 
reduction at 60 seconds and 42% reduction at 240 seconds. 
4. MATERIALS AND METHODOLOGY 
 The materials used in this study include: 
1) Pneumatic double tourniquet 
2) Esmarch bandage 
3) Intravenous cannulas – 20 G and 22G 
4) Disposable syringes  
5) Intravenous solutions 
6) Infusion sets 
7) Local anaesthetic agents – 2% Plain Lignocaine (Xylocard) 
8) Additive agents -  Paracetamol or Normal saline 
 
FIGURE 11.  MATERIALS USED IN THE STUDY 
 
METHODOLOGY: 
 
Study design  :          Prospective Randomised double blinded study          
Study population  :  ASA I &II patients posted for upper limb surgeries 
Sample size  :          60 patients 
Study period : August 2013 – March 2015 
Study conducted : PSG Institute of Medical Sciences, Coimbatore 
 
  Ethical committee approval (August 2013) obtained prior to the start of study. 
60 patients of American Society of Anaesthesiologists (ASA) physical status 
belonging to I or II who were scheduled for upper limb extremity surgeries were 
included in the study after obtaining informed written consent. 
The study group patients were assigned into two groups as Group 1 and Group 
2, comprising of 30 patients each.  IVRA was performed using 10 ml of 2% 
Lignocaine with 30 ml of Paracetamol in Group 1 patients and 10 ml of 2% 
Lignocaine with 30 ml of Normal saline in Group 2. 
 
 
 
   INCLUSION CRITERIA: 
1. ASA I and II patients 
2. Age between 20-60 yrs 
3. Upper limb extremity surgeries of duration not exceeding  60 minutes 
 
EXCLUSION CRITERIA: 
1. History of allergy to local anaesthetics  
2. Expected duration of surgery more than 60 minutes 
3.  Raynaud’s disease  
4. Sickle cell anaemia 
5. Coagulation disorders 
 
PROCEDURE: 
Simple randomization was done and assigned into two groups (with 30 patients 
in each group as Group -1 and Group - 2).   
According to ASA starvation guidelines patients were kept nil per oral status 
overnight and  pre-medicated with Tablet Ranitidine 150 mg and Tablet Diazepam 5 
mg  the night prior to surgery and  on the morning  of surgery. 
Anaesthesia machine safety checklist including resuscitation equipments, 
emergency drugs and tourniquet equipments were kept ready before the patient 
arrived in the operating room (OR). Starvation status and surgical consent confirmed 
in the preoperative room before the patient was shifted inside the operating room.  
Preinduction monitors like ECG leads, Non invasive blood pressure (NIBP) 
cuff and pulseoximeter were connected and baseline readings noted. All the patients 
were explained about the Visual Analogue Scale (VAS) prior to the start of the 
procedure.  
The syringes were loaded by the principal investigator in the study. 
Two intravenous cannulas were secured according to the universal aseptic 
precautions – one on the dorsum of operative hand as distal as possible to field of 
surgery for IVRA (22 G) and another on the non operative hand for crystalloid 
infusion (20 G).  
The double pneumatic tourniquet a proximal cuff and distal cuff, were applied 
to the operative limb after padding the limb. Blood pressure cuff and pulse oximeter 
were applied to the opposite limb. 
 FIGURE 12. INTRAVENOUS CANNULATION WITH TOURNIQUET 
ON THE OPERATIVE LIMB 
The operative arm was elevated for 2 minutes and exsanguination was aided 
with an Esmarch bandage.  
 
FIGURE 13. LIMB EXSANGUINATION 
The proximal cuff was inflated to 100 mmHg above patient’s systolic blood 
pressure. Circulatory isolation of arm was verified by inspection, absence of radial 
pulse, and a loss of the pulse oximetry tracing. 
The solutions were injected by an anaesthesiologist blinded to the study drugs. 
After injecting the study drug, the sensory block was evaluated by pinprick test every 
30 seconds until start of surgery with 22-guage needle in median, ulnar and radial 
nerve innervated areas of the hand and forearm. 
 
FIGURE 14. IVRA ADMINISTRATION 
Motor nerve functions were assessed by asking patients to flex and extend their 
wrist and fingers, complete block was achieved when no voluntary movement was 
possible. After complete sensory and motor blocks were achieved, the distal 
tourniquet was inflated to 100 mmHg, approximately 15 minutes later the proximal 
tourniquet was released, and surgery was started. 
Vital signs like MAP, HR, and SpO2 were recorded before and after application 
of tourniquet and monitored continuously during the procedure at 5, 10, 15, 20, 30, 
40, 50 minutes interval till the release of tourniquet.  
Pain was assessed using a 10cm visual analogue scale. If the patient reported a 
VAS > 4, rescue analgesic of 1 mcg/kg Fentanyl was intravenously given and the 
requirement for analgesics was recorded. 
 
 
FIGURE 15. VISUAL ANALOGUE SCALE 
 
The tourniquet should not be deflated till 30 minutes after the start of the 
procedure and not to be inflated more than 2 hours. At the end of the surgery, sensory 
and motor recovery time was noted.  
 Patient satisfaction was graded as excellent, good, moderate and poor. 
Surgeons blinded to the study were asked to grade the procedure based on the 
operative conditions and dryness of the field of surgery. The grading was scored as 
perfect, acceptable, poor and unsuccessful. 
The first analgesic requirement after the deflation of tourniquet was noted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. OBSERVATION AND RESULTS 
STATISTICAL ANALYSIS: 
In this study, 60 patients were selected after considering the inclusion and 
exclusion criteria. Consent was obtained from all the 60 patients and were divided into 
2 groups with 30 patients in each group.  
 
Group 1 received 30 ml of Paracetamol and 10 ml of 2% Lignocaine (preservative 
free (PF)) 
Group 2 received 30 ml of Normal Saline and 10 ml of 2% Lignocaine (preservative 
free (PF)) 
 
Statistical analysis was performed using Statistical Package for the Social 
Sciences (SPSS) version 19.  
Chi-square test and paired ‘t’ test was used for analysis.  
“p value of  <0.05” was considered to be statistically significant in this 
study and “p value of <0.001” was considered to be statistically highly significant. 
 
 
 
 MEAN AGE DISTRIBUTION OF STUDY G
 
 
GROUP 
 
 
MEAN AGE
 
 
1 
 
 
42.87 
 
 
2 
 
 
39.37 
 
TABLE 1: MEAN AGE DISTRIBUTION
The average mean age distribution in group 1 and group 2 were 42.87 and 
39.37 respectively. The Chi square test and p value is 0.276 which is > 0.05 shows 
that there is no statistically significant difference in mean age between two groups. 
FIGURE 16: MEAN AGE DIS
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GROUP 1
GROUP 2
 AGE GROUP DISTRIBUTION
AGE IN 
YEARS 
GROUP 
No. of Patients
20 - 30 6 
31 – 40 8 
41 – 50 7 
51 - 60 9 
Total 30 
Mean Age in 
years ± S.D 42.87
x
2 
p value 
 
TABLE 2: AGE GROUP DISTRIBUTION
 There is no statistically significant difference in age group distribution 
between two groups as ‘p’ value is 0.276 which is >0.05.
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GROUP 1
GROUP 2
 SEX DISTRIBUTION 
 
SEX 
 
 
GROUP 1 
 
Males 
 
18 (60%) 
 
Females 
 
12 (40%) 
 
Total 
 
30 (100%) 
TABLE 3: SEX DISTRIBUTION
The p value is 0.602 which is > 0.05 and this shows that there is no statistically 
significant difference in sex distribution between two groups.
 
FIGURE 18 : SEX DISTRIBUTION
0
2
4
6
8
10
12
14
16
18
20
MALE
N
O
.O
F
 P
A
T
IE
N
T
S
 
GROUP 2 
 
TOTAL 
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16 (53.3%) 
 
34 (56.7%) 
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26 (43.3%) 
 
30 (100%) 
 
60 (100%) 
 
 
 
 
 
FEMALE
SEX DISTRIBUTION
 
P 
 
 
 
0.602 
 
GROUP 1
GROUP 2
 ASA GRADING DISTRIBUTION
    
 
ASA 
 
 
GROUP 1 
 
1 
 
 
20 (66.7%) 
 
2 
 
 
10 (33.3%) 
 
Total 
 
 
30 (100%) 
 
TABLE 4: ASA GRADING 
The p value is 0.573 which is > 0.05 showing no statistically 
difference in ASA grading distribution between two groups.
 
FIGURE 19 : ASA GRADING 
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0.573 
significant 
 
GROUP 1
GROUP 2
TYPE OF SURGERY 
 
GROUP 
 
 
Carpal 
tunnel 
release 
Ganglion 
Excision
 
1 
 
 
7  
 
2 
 
 
4  
 
Total 
 
 
11 
 
TABLE 5: TYPE OF SURGERY PERFORMED
By Chi square test, x
statistically significant difference in terms of type of surgery performed between two 
groups. 
FIGURE 20 : TYPE OF SURGERY PERFORMED IN EACH GROUP
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 ONSET OF SENSORY AND MOTOR BLOCK TIME 
 
GROUP 
 
 
N 
 
MEAN 
 
SD 
 
t 
 
p 
 
Onset of 
 
Sensory 
 
Block (mins) 
 
 
1 
 
30 
 
 
 
5.60 
 
 
 
1.589 
 
 
 
3.734 
 
 
 
 
0.001 
 
2 
 
30 
 
7.13 
 
1.592 
 
 
Onset of 
 
Motor 
 
Block (mins) 
 
 
1 
 
 
30 
 
 
 
8.70 
 
 
 
2.521 
 
 
 
 
 
5.194 
 
 
 
0.001 
 
2 
 
30 
 
12.27 
 
2.791 
 
 
TABLE 6: ONSET OF SENSORY AND MOTOR BLOCK TIME 
 
 
The paired t test value was 3.734 and p < 0.001 which shows that there is 
statistically highly significant difference in between two groups in terms of the 
onset of sensory block time. 
The paired t test value was 5.194 and p < 0.001 which shows that there is 
statistically highly significant difference in between two groups in terms of the 
onset of motor block time. 
 
 
 
SENSORY AND MOTOR RECOVERY TIME 
 
GROUP 
 
N 
 
MEAN 
 
SD 
 
t 
 
P 
 
Sensory 
 
 Recovery 
 
 Time (mins) 
 
 
1 
 
 
 
30 
 
7.60 
 
1.102 
 
 
5.614 
 
 
0.001 
 
2 
 
30 
 
5.60 
 
1.610 
 
Motor  
 
Recovery 
 
 Time (mins) 
 
 
1 
 
 
 
30 
 
 
8.90 
 
 
2.139 
 
 
 
2.443 
 
 
0.018 
 
2 
 
30 
 
10.37 
 
2.498 
 
TABLE 7: SENSORY AND MOTOR RECOVERY TIME 
 
The paired t test value was 5.614 and p value < 0.001 which shows that there 
is statistically highly significant difference in between the groups in terms of the 
sensory recovery time. 
 
The paired t test value was 2.443 and p value 0.018 which shows that there is 
statistically significant difference between the groups in terms of the motor 
recovery time. 
 
 FIGURE 21 : ONSET OF SENSORY AND MOTOR BLOCK TIME
 
FIGURE 22 : SENSORY AND MOTOR
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 RECOVERY TIME 
Onset of Motor Block 
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GROUP 1
GROUP 2
Motor Recovery Time(Minutes)
GROUP 1
GROUP 2
 
 
INTRAOPERATIVE VAS SCORE
 
GROUP 
 
 
N 
 
1 
 
 
30 
 
2 
 
 
30 
 
TABLE 8: INTRAOPERATIVE VAS SCORE
The paired t test is 3.116 and 
statistically significant difference
groups. 
 
FIGURE 23: INTRAOPERATIVE VAS SCORE
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SD 
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p value is 0.003 which shows 
 in the intraoperative VAS score between
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0.003 
there is a 
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GROUP 1
GROUP 2
SURGEON SATISFACTION GRADING 
 
Surgeon 
Satisfaction 
Grading 
 
Group 1 
 
Group 2 
 
Total 
 
x
2
 
 
p 
 
1 
 
14 (46.7%) 
 
 
6 (20%) 
 
20 (33.3%) 
 
 
 
 
 
 
 
4.800 
 
 
 
 
 
 
 
0.028 
 
2 
 
16 (53.3%) 
 
 
24 (80%) 
 
40 (66.7%) 
 
3 
 
0 
 
 
0 
 
0 
 
4 
 
0 
 
 
0 
 
0 
 
Total 
 
30 (100%) 
 
 
30 (100%) 
 
60 (100%) 
 
 
TABLE 9: SURGEON SATISFACTION GRADING 
 
The p value is 0.028 which is < 0.05 shows there is statistically significant 
difference between two groups with regard to surgeon satisfaction. 
 
 
 
 
 PATIENT SATISFACTION GRADING 
 
PATIENT 
SATISFACTION 
GRADING 
 
GROUP 1 
 
GROUP 2 
 
TOTAL 
 
X2 
 
p 
 
1 
 
 
7 (23.3%) 
 
2 (6.7%) 
 
9 (15%) 
 
 
 
 
 
 
7.541 
 
 
 
 
 
 
0.023 
 
2 
 
 
18 (60%) 
 
14 (46.7%) 
 
32 (53.3%) 
 
3 
 
 
5 (16.7%) 
 
14 (46.7%) 
 
19 (31.7%) 
 
4 
 
 
0 
 
0 
 
0 
 
TOTAL 
 
 
30 (100%) 
 
30 (100%) 
 
60 (100%) 
 
 
TABLE 10: PATIENT SATISFACTION GRADING 
 
 
The p value is 0.023 which is < 0.05 which shows there is a statistically 
significant difference between two groups in terms of patient satisfaction. 
 
 
FIGURE 24 : SURGEON SATISFACTION GRADING
FIGURE 25 : PATIENT SATISFACTION GRADING
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GROUP 1
GROUP 2
GROUP 1
GROUP 2
 FENTANYL REQUIREMENT
 
FENTANYL 
REQUIREMENT 
 
GROUP 1
 
YES  
 
 
4 (13.3%)
 
NO  
 
 
26 (86.7%)
 
TOTAL 
 
 
30 (100%)
 
TABLE 11: FENTANYL REQUIREMENT
The Chi-square test value
is a statistically highly significant
Fentanyl requirement intraoperatively
FIGURE 26 : FENTANYL REQUIREMENT
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GROUP 2 
 
TOTAL 
 
x
2
 
 
 
17 (56.7%) 
 
21 (35%) 
 
 
 
 
12.381 
 
 
13 (43.3%) 
 
39 (65%) 
 
 
30 (100%) 
 
60 (100%) 
 INTRAOPERATIVELY 
 is 12.381. The p value is 0.001 which shows there 
 difference between two groups in terms of 
. 
 INTRAOPERATIVELY
No
FENTANYL REQUIREMENT
 
p 
 
 
 
 
0.001 
 
 
GROUP 1
GROUP 2
FENTANYL CONSUMPTION IN MICROGRAMS (mcg)
 
GROUP 
 
 
N 
 
1 
 
 
30 
 
2 
 
 
30 
TABLE 12: FENTANYL CONSUMPTION INTRAOPERATIVELY
The p value is 0.001 which shows there is a statistically highly significant 
difference in between the grou
analgesic intraoperatively. 
 
FIGURE 27: FENTANYL CONSUMPTION INTRAOPERATIVELY
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 as rescue 
 
 
GROUP 1
GROUP 2
POST OPERATIVE ANALGESIC REQUIREMENT
POST 
OPERATIVE 
ANALGESIA 
 
GROUP 1 
 
YES 
 
 
9 (30%) 
 
NO 
 
 
21 (70%) 
 
TOTAL 
 
 
30 (100%) 
 
TABLE 13: POSTOPERATIVE ANALGESIC
The Chi-square value is 
a statistically highly significant
operative analgesic requirement following tourniquet deflation.
FIGURE 28: POSTOPERATIVE ANALGESIA REQUIREMENT
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6. DISCUSSION 
IVRA was first introduced by August Bier in the year 1908. This technique is 
commonly known as Bier’s block in commemoration of its founder. IVRA is a simple 
technique, easy to perform, providing adequate analgesia intraoperatively and 
decreased postoperative analgesic requirements, while the circulation is occluded. It 
can be performed in extremities requiring surgical intervention where general 
anaesthesia may be contraindicated either due to their comorbid conditions or 
inadequate fasting status. 
IVRA technique provides a simple, easy application, cost effective and time 
saving anaesthesia which makes it as a day care procedure resulting in early discharge 
allowing them to resume normal activities at the earliest. 
Many local anaesthetic agents like Procaine, Mepivacaine, Bupivacaine, 
Ropivacaine and Prilocaine have been used, but Lignocaine has been popularised as it 
was found to have less complications when compared with other agents. This 
technique has the disadvantages of local anaesthetic toxicity, tourniquet pain and 
inadequate post operative analgesia. These factors have been overcome by changing 
the local anaesthetics used, modifying the technique and adding additives to local 
anaesthetics11.   
In our study, we investigated whether the addition of Paracetamol to IVRA 
solution decreased tourniquet pain, decreased intraoperative use (Fentanyl) and 
enhanced the sensory and motor block duration by increasing the quality of IVRA. 
However, in our study we also demonstrated a decrease in postoperative pain score 
and analgesic requirement. 
SELECTION OF DRUGS AND DOSAGE: 
Lignocaine was the local anaesthetic chosen as it is the least toxic agent among 
the others. Usually 1-2 mg/kg is given for attenuating cardiovascular response during 
endotracheal intubation or for ventricular arrhythmias.  
In IVRA, there is a tourniquet placed over the upper arm requiring adequate 
analgesia to prevent intraoperative tourniquet pain, hence a dose of 3mg/kg 2% 
Lignocaine was required13. In this study, a fixed dose of 10 ml of 2% Lignocaine 
(Xylocard-preservative free) was used and made to a total of 40 ml making it as 0.5% 
Lignocaine which produced adequate analgesia without serious adverse effects69, 70. 
In our study, we used Paracetamol as an additive to confirm whether there was 
a decrease in intraoperative pain, minimal or decreased opioid usage intraoperatively, 
along with reduced postoperative analgesic requirement and favourable effects on 
sensory and motor block.  
The dose of Paracetamol was fixed to 30 ml amounting to 300 mg, as total 
volume required was 40 ml for each group. If a dose more than 300 mg of 
Paracetamol was used, there would be more volume requiring the local anaesthetic 
dose to be reduced, that would lead to inadequate sensory and motor blockade14. 
Myoung JK et al69 used Fentanyl 1 microgram /kg for tourniquet pain and 50 
mg Tramadol for postoperative pain. Sen H et al14 used Fentanyl 1 microgram/ kg if 
patient had VAS> 4 and 75 mg Diclofenac  for post operative pain. 
In our study, we used Fentanyl 1 microgram/kg for intraoperative / tourniquet 
pain or if VAS > 4 requiring analgesia and it was found to be statistically significant 
which was in concordance with Sen H et al14.   
We also noted post tourniquet deflation analgesic request time along with 
analgesic supplementation time as per the treating physician orders and found it to be 
statistically significant. Sen H et al14 used Diclofenac in his study and noted the 
decreased Diclofenac requirement in post tourniquet deflation period which was 
statistically significant. 
AGE DISTRIBUTION: 
Elhakim M and Sadek RA71 carried out IVRA on patients between 25 – 55 
years. Palecha S et al73 used IVRA on patients above 20 years of age. Sanjay Kherde 
et al72 used age group of 15 – 55 years in his study.   
In our study, after reviewing the literature we selected the study group in the 
age between 20 – 60 years. The mean age distribution in our study was 42.87 ± 11.57 
in Group 1 and 39.37 ± 13.04 in Group 2 which was found to be statistically 
insignificant in coherence with the studies. 
 
 
SEX DISTRIBUTION:  
 Out of 60 patients in our study, the sex distribution was 18:12 (Male: Female) 
in Group 1 and 16:14 (Male: Female) in Group 2. Statistical analysis was insignificant 
with regard to sex distribution in both the groups in our study, which was in 
accordance with Vishala et al11. 
ASA GRADING: 
In our study, we included patients belonging to ASA I and ASA II in both the 
groups and found to be statistically insignificant. This study correlates with the Sen et 
al14 demographic studies on similar ASA distribution. 
PREMEDICATION: 
Sen H et al14 premedicated patients with 0.07 mg/kg of Midazolam i.m and 
0.01 mg/kg of Atropine i.v 45 minutes before surgical procedures.  
Supplementation of premedication to the patients preoperatively ensured 
allaying anxiety and for better assessment of the quality of analgesia.  In this study, 
we premedicated the patients preoperatively with Tablet Ranitidine 150 mg and Tablet 
Diazepam 5 mg on the day prior to surgery in the night and 2 hours prior to surgery on 
the day of surgery. 
 We believed that premedicating the patients with an anxiolytic agent would 
help in improving the patients co operation for the procedure. 
 
INTRAOPERATIVE PAIN: 
Tourniquets are used in IVRA to restrict the drugs from entering beyond the 
cuff into systemic circulation causing untoward consequences. It is also used to 
provide analgesia and motor blockade distal to the tourniquet. 
Chandrashekara PM et al74 used single rubber latex bandage as a tourniquet 
above the site of surgery. He noted the tourniquet pain and discomfort in surgeries that 
prolonged for more than 40-50 minutes. 
Holmes C et al1, Sorbie C and Chancha P24 and Janardhan et al75 used double 
tourniquet with the second tourniquet placed on the anaesthetised portion of the 
extremity distal to the proximal one to prevent tourniquet pain and discomfort. 
In our study, we used a double pneumatic tourniquet placing the first tourniquet 
on the proximal portion of the extremity to be operated and the second tourniquet 
distal to the proximal one. Group 1 patients in our study had very negligible 
intraoperative pain / discomfort during procedure, but Group 2 patients reported with 
pain intraoperatively, presumably tourniquet pain.  
EXSANGUINATION: 
IVRA technique is successful when there is proper tourniquet placement and 
adequate exsanguination1. 
Holmes C et al1 and Chandrashekara PM et al74 achieved exsanguination either 
by simple gravity draining method or by using Esmarch bandage and combined both 
in some cases.  
Blond L et al16 showed there was 69% reduction in blood volume in the limb 
after exsanguination using Esmarch bandage. 
In our study, we used the combination of limb elevation and Esmarch bandage 
for exsanguination. 
 ONSET OF SENSORY BLOCK TIME: 
In our study, the mean time of onset of sensory block was 5.60 ± 1.589 minutes 
in Group 1 and 7.13 ± 1.592 minutes in Group 2 patients. The p value < 0.001 shows 
there is statistically highly significant difference between two groups in terms of time 
of onset of sensory block. 
The observation of the present study is in accordance with regards to the mean 
time of onset of sensory block by Myoung Jin Ko and Jeong Han Lee et al69. He 
reported a similar statistically significant difference in his IVRA study, in patients 
who received 40 ml of 0.5% Lignocaine in one group and 0.5% Lignocaine diluted 
with Acetaminophen 300 mg to a total volume of 40ml. 
ONSET OF MOTOR BLOCK TIME: 
In our study amongst patients in Group 1, the average onset of motor block 
time was 8.70 ± 2.521 minutes and in Group 2 it was 12.27 ± 2.791 minutes. The p 
value < 0.001 shows that there is statistically highly significant difference among two 
groups in terms of time of onset of motor block. 
The observation of the present study is in accordance with the observations of 
Sen H, Kulahci Y et al14 who stated similar statistically significant difference in their 
study population with the mean time motor block onset 12 ± 4 minutes in patients who 
received 40 ml of 0.5% Lignocaine and 8 ± 4 minutes in patients who received 0.5% 
Lignocaine diluted with Acetaminophen 300 mg to a total volume of 40 ml. . 
SENSORY BLOCK RECOVERY TIME: 
In our study, the sensory recovery time was 7.60 ± 1.102 minutes in Group 1 
and 5.60 ± 1.610 minutes in Group 2. The p value < 0.001 showed that there is 
statistically highly significant difference with regard to the onset of the sensory 
recovery time between two groups. 
The observations of the present study are in accordance with the statistical 
observation of Sen H, Kulahci et al14, who reported the mean time of sensory block 
recovery time was 5 ± 3 minutes in patients who received 40 ml of 0.5% Lignocaine 
and 8 ± 2 minutes in patients who received 0.5 % Lignocaine diluted with the 
Acetaminophen 300 mg to a total volume of 40 ml. 
MOTOR BLOCK RECOVERY TIME: 
In our study, the motor recovery time was 8.90 ± 2.139 minutes in Group 1 and 
10.37 ± 2.498 minutes in Group 2. The p value 0.018 showed that there is statistically 
significant difference between two groups in terms of motor recovery time. 
The observations of the present study are in accordance with the statistical 
observation of Sen H, Kulahci et al14, who reported the mean time of motor block 
recovery time was 6 ± 2 minutes in patients who received 40 ml of 0.5% Lignocaine 
and 8 ± 4 minutes in patients who received 0.5 % Lignocaine diluted with the 
Acetaminophen 300 mg to a total volume of 40 ml. 
INTRAOPERATIVE ANALGESIC REQUIREMENT: 
In our study, 4 patients out of 30 required Fentanyl consumption 
intraoperatively in Group 1 and 17 patients out of 30 in Group 2 and proved to be 
statistically significant with a p value of 0.003.  This observation was concurrent with 
that of Sen H et al14. 
In our study, the mean Fentanyl consumed was 8.33 ± 21.827 micrograms in 
Group 1 and 38 ± 37.820 micrograms in Group 2, p value < 0.001 showed that there is 
statistically highly significant difference between two groups in terms of Fentanyl 
consumption as rescue analgesic intraoperatively. 
INTRAOPERATIVE VAS SCORE: 
The mean VAS pain score intraoperatively was 2.17 ± 1.621 in Group 1 and 
3.80 ± 2.369 in Group 2. The p value 0.003 showed that there is statistically 
significant difference in the intraoperative VAS score between two groups.  
This observation was in accordance with observation obtained in Sen H et al14 
where intraoperative VAS scores seen at 20 and 30 minutes were significantly lower 
in Group 2 which was 10 ml 3mg/kg Lignocaine with 300mg Paracetamol similar to 
the present study. 
 
 POST DEFLATION ANALGESIC REQUIREMENT: 
 Out of 30 patients in each group in our study, 9 patients required analgesia 
following tourniquet deflation in Group 1 and 25 patients in Group 2; which was 
statistically significant between two groups with p value < 0.05 
This observation coincides with Sen H et al14 and Myoung Jin Ko et al69 where 
they showed a statistically significant difference between two groups with a p value 
<0.05 using Diclofenac and Tramadol respectively. 
SURGEON SATISFACTION: 
 Out of 30 patients in each group in our study, surgeon satisfaction grade was 
excellent in 14 patients in Group 1 and 6 patients in Group 2. The grade was good in 
16 patients of Group 1 and 24 patients of Group 2. 
 There was a statistically significant difference between two groups as the p 
value is 0.028 (which is < 0.05) with regard to surgeon satisfaction in our study. 
PATIENT SATISFACTION: 
Out of 60 patients in our study, 7 patients from Group 1 and 2 patients from 
Group 2 gave excellent grading (Grade 1), 18 patients from Group 1 and 14 patients 
from Group 2 gave good grading (Grade 2) and 5 patients from Group 1 and 14 
patients from Group 2 gave moderate grade (Grade 3). 
There was a statistically significant difference between two groups as p is 
0.023 (< 0.05) with regard to patient satisfaction in our study.   
7. SUMMARY 
 The IVRA study entitled “Efficacy of Paracetamol when added as an adjunct to 
Lignocaine in Intravenous Regional Anaesthesia” was undertaken at PSG IMSR, 
Coimbatore from 8th August 2013 to 31st March 2015. The study population consisted 
of 60 patients belonging to ASA class I and II who were allocated into two groups as 
  Group 1 – 10 ml 2 % Lignocaine (PF) with 30 ml Paracetamol and 
  Group 2 – 10 ml 2 % Lignocaine (PF) with 30 ml Normal Saline 
 The following parameters were studied in our IVRA study  
1. Demographic details like age and sex distribution 
2. ASA distribution and type of surgery performed 
3. Intraoperative tourniquet pain assessed by VAS  
4. Onset of sensory and motor block 
5. Sensory and Motor block recovery time 
6. Fentanyl requirement intraoperatively  
7. Surgeon and Patient satisfaction in IVRA technique 
8. Postoperative analgesic requirement 
  
 
PARAMETERS 
 
GROUP - 1 
 
GROUP -2 
 
p VALUE 
 
Age (Years) 
 
Sex (Male / Female) 
 
ASA (I / II) 
 
Onset of Sensory Block (Mins) 
 
Onset of Motor Block (Mins) 
 
Sensory Block Recovery Time (Mins) 
 
Motor Block Recovery Time (Mins) 
 
Intraoperative VAS  
 
Fentanyl Consumption (mcg) 
 
Fentanyl required intraoperatively 
 
Surgeon Satisfaction (Grade 1:2:3:4) 
 
Patient Satisfaction  (Grade 1:2:3:4) 
 
Postoperative Analgesic Requirement 
                                      (Yes / No) 
 
42.87 ± 11.58 
 
18 / 12 
 
20 / 10 
 
5.60 ± 1.58 
 
8.70 ± 2.52 
 
7.60 ± 1.10 
 
8.90 ± 2.13 
 
2.17 ± 1.62 
 
8.33 ± 21.82 
 
4 
 
14:16:0:0 
 
7:18:5:0 
 
9 / 21  
 
39.37 ± 13.04 
 
16 / 14 
 
22 / 8 
 
7.13 ± 1.59 
 
12.27 ± 2.79 
 
5.60 ± 1.6 
 
10.37 ± 2.49 
 
3.80 ± 2.36 
 
38 ± 37.82 
 
17 
 
6:24:0:0 
 
2:14:14:0 
 
25 / 5  
 
> 0.05 
 
0.602 
 
0.573 
 
< 0.001 
 
< 0.001 
 
< 0.001 
 
0.018 
 
0.003 
 
< 0.001 
 
< 0.001 
 
0.028 
 
0.023 
 
< 0.001 
 
TABLE 14: SUMMARY OF THE STUDY 
 
  
8. CONCLUSION 
 
 To conclude from our study, that the administration of Paracetamol as an 
adjunct to Lignocaine in IVRA, was found to be efficacious and it provided significant 
shortening in the onset of sensory block, a decrease in the intraoperative analgesic 
requirement and an improvement in the post operative analgesia with a reduced need 
for analgesics in the post operative period. 
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10. ANNEXURES 
Proforma 
Name:                               Age/Sex:                   IP no: 
OP no:                              Dept/Unit:                 ASA: 
Group: 
Time of injection of solution: 
Onset of sensory block          : 
Onset of motor block             : 
Monitoring chart: 
TIME(min) PR MAP SpO2 
Baseline    
5    
10    
15    
20    
30    
40    
50    
After release    
10 min after 
release 
   
 
Tourniquet pain : VAS :       
Rescue Analgesic          : 
 
Excellent   :       Good          Moderate           Poor           
 
Surgeon Satisfaction: 
Perfect           Acceptable     :   Poor            Unsuccessful         
 
Sensory Recovery time : 
Motor Recovery time    : 
First Analgesic Time       : 
 
Patient Satisfaction         :  
Excellent             Good           Moderate           Poor                    
 
 
 
  
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
 
I / We (write name of the investigator(s) here),   DR.S.SULEKHA , am / are carrying 
out a study on the topic: EFFICACY OF PARACETAMOL WHEN ADDED AS AN 
ADJUNCT TO LIGNOCAINE IN INTRAVENOUS REGIONAL ANAESTHESIA 
 
As part of my / our research project being carried out under the aegis of the 
Department of: ANAESTHESIOLOGY   
 
(Applicable to students only): My / our research guide is: DR.S.MUSHAHIDA 
 
The justification for this study is:   Paracetamol added as an adjunct to lignocaine  has 
been shown to provide decreased tourniquet pain ,increased anaesthesia quality and 
decreased postoperative analgesic consumption.  
 
The objectives of this study are:  
 
Primary Objective: To determine the efficacy of paracetamol when added as adjuvant 
to lignocaine for intravenous regional anaesthesia. 
 
Secondary Objective: to compare the 
1) Onset of sensory and motor block in both groups. 
2) Recovery time in both groups. 
3) Requirement of post operative analgesia. 
 
 
Sample size: __60 convenient sample size__.  
 
Study volunteers / participants are (specify population group & age group): ASA 1-
2,AGE GROUP-20-60 yrs .  
 
Location: _PSGIMSR.  
 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will be 
carrying out:  
 
Initial interview (specify approximate duration):20 minutes.  
 
Data collected will be stored for a period of fifteen years. We will / will not use the 
data as part of another study. 
 
Health education sessions: Number of sessions: __1_. Approximate duration of 
each session:  
 
___20__minutes.  
 
Clinical examination (Specify details and purpose):  
 
Blood sample collection: Specify quantity of blood being drawn: ___________ml.  
 
No. of times it will be collected: _______________.  
 
Whether blood sample collection is part of routine procedure or for research (study) 
purpose:   
 
1. Routine procedure 2. Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: 
_______________________________ 
 
Whether blood sample collected will be stored after study period: Yes / No, it will 
be destroyed 
 
Whether blood sample collected will be sold: Yes / No  
 
Whether blood sample collected will be shared with persons from another institution:
 Yes / No 
 
Medication given, if any, duration, side effects, purpose, benefits:  
 
Whether medication given is part of routine procedure: Yes / No (If not, state reasons 
for giving this medication) 
 
Whether alternatives are available for medication given: Yes / No (If not, state reasons 
for giving this particular medication) 
 
Final interview (specify approximate duration):_________ mts. If photograph is 
taken, purpose:  
 
Benefits from this study:  
Easy to administer 
Low incidence of block failure 
Safe technique when used appropriately 
Rapid onset and recovery 
Muscle relaxation for the surgeon 
 
Risks involved by participating in this study:  
Tourniquet discomfort- tourniquet pain may occur 20-30 minutes after 
inflation. 
Rapid return of sensation after tourniquet release resulting in subsequent pain 
Toxic  reactions from malfunctioning tourniquets or deflating the tourniquets 
prior to 20-25 minutes. 
Sudden cardiovascular collapse or seizures may occur if local anaesthetic is 
released into the circulation too early. 
 
How the results will be used:  
 
If you are uncomfortable in answering any of our questions during the course of the 
interview / biological sample collection, you have the right to withdraw from the 
interview / study at anytime. You have the freedom to withdraw from the study at 
any point of time. Kindly be assured that your refusal to participate or withdrawal at 
any stage, if you so decide, will not result in any form of compromise or 
discrimination in the services offered nor would it attract any penalty. You will 
continue to have access to the regular services offered to a patient. You will NOT be 
paid any remuneration for the time you spend with us for this interview / study. The 
information provided by you will be kept in strict confidence. Under no circumstances 
shall we reveal the identity of the respondent or their families to anyone. The 
information that we collect shall be used for approved research purposes only. You 
will be informed about any significant new findings - including adverse events, if any, 
– whether directly related to you or to other participants of this study, developed 
during the course of this research which may relate to your willingness to continue 
participation. 
 
Consent: The above information regarding the study, has been read by me/ read to 
me, and has been explained to me by the investigator/s. Having understood the same, I 
hereby give my consent to them to interview me. I am affixing my signature / left 
thumb impression to indicate my consent and willingness to participate in this study 
(i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:      Witness: 
 
 
